newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

  • Cogent Biosciences announced two data presentations at the European Hematology Association Congress in Stockholm, scheduled for June 11-14, 2026.
  • Pivotal Phase 2 APEX trial data for bezuclastinib in Advanced Systemic Mastocytosis was accepted for an oral presentation on June 13, 2026.
  • Preclinical data regarding the JAK2 V617F program and the novel inhibitor CGT1145 was accepted for poster presentation on June 12, 2026.
  • The oral presentation titled "Efficacy and Safety of Bezuclastinib in Patients With Advanced Systemic Mastocytosis" will be delivered by Dr. Daniel DeAngelo.
  • The poster presentation on bezuclastinib pathobiology will be presented by Dr. Tracy George.
  • The JAK2 V617F poster presentation will be presented by Mark J Chicarelli.
  • Bezuclastinib is a selective tyrosine kinase inhibitor targeting KIT D816V mutations driving systemic mastocytosis and exon 17 mutations in GIST.
  • Cogent Biosciences is developing additional targeted therapies for mutations in ErbB2, PI3Kα, KRAS, and JAK2.